DAHANCA 33: functional image-guided dose-escalated radiotherapy to patients with hypoxic squamous cell carcinoma of the head and neck (NCT02976051)

References

• Overgaard J, Jovanovic A, Godballe C, et al. The Danish Head and Neck Cancer database. Clin Epidemiol. 2016;8:491–496.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16(4):234–249.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Improving radiotherapy of squamous cell carcinoma of the head and neck (HNSCC) through a continuous process of biological based clinical trials − a 40-year experience from the Danish Head and Neck Cancer Group – DAHANCA. Eur J Cancer. 2017;72:S102.
   Web of Science ®Google Scholar
• Lassen P, Lacas B, Pignon JP, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 2018;126(1):107–115.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–4074.
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77(1):18–24.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Busk M, et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–687.
   PubMed Web of Science ®Google Scholar
• Mortensen LS, Johansen J, Kallehauge J, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105(1):14–20.
   PubMed Web of Science ®Google Scholar
• Saksø M, Mortensen L, Primdahl H, et al. OC-0268: FAZA PET hypoxia as a marker of loco-regional recurrence in HNSCC? Results from the DAHANCA 24 trial. Radiother Oncol. 2018;127:S136.
   PubMed Web of Science ®Google Scholar
• Peters LJ, Ang KK. The role of altered fractionation in head and neck cancers. Semin Radiat Oncol. 1992;2(3):180–194.
   PubMedGoogle Scholar
• Saksø M, Andersen E, Bentzen J, et al. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncol. 2019;58(10):1495–1501.
   PubMed Web of Science ®Google Scholar
• Evensen JF, Sand Hansen H, Overgaard M, et al. DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). Acta Oncol. 2019;58(10):1502–1505.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854.
   PubMed Web of Science ®Google Scholar
• Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237.
   PubMed Web of Science ®Google Scholar
• Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6(1):28.
   PubMedGoogle Scholar
• Blanchard P, Landais C, Lacas B, et al. Update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC). Radiother Oncol. 2017;122:9.
   Web of Science ®Google Scholar
• Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – a systematic review and meta-analysis. Radiother Oncol. 2011;100(1):22–32.
   PubMed Web of Science ®Google Scholar
• Saksø M, Jensen K, Andersen M, et al. OC-041 DAHANCA 28a: phase I/II study of acc. hyperfractionated RT, cisplatin and nimorazole in P16-LAHNSCC. Radiother Oncol. 2019;132:21–22.
   Web of Science ®Google Scholar
• Hansen CR, Johansen J, Kristensen CA, et al. Quality assurance of radiation therapy for head and neck cancer patients treated in DAHANCA 10 randomized trial. Acta Oncol. 2015;54(9):1669–1673.
   PubMed Web of Science ®Google Scholar
• Welz S, Mönnich D, Pfannenberg C, et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol. 2017;124(3):526–532.
   PubMed Web of Science ®Google Scholar
• Pigorsch SU, Wilkens JJ, Kampfer S, et al. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Radiat Oncol. 2017;12:45.
   PubMed Web of Science ®Google Scholar
• Stieb S, Eleftheriou A, Warnock G, et al. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. Eur J Nucl Med Mol Imaging. 2018;45(12):2201–2217.
   PubMed Web of Science ®Google Scholar
• Ureba A, Lindblom E, Dasu A, et al. Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription. Acta Oncol. 2018;57(4):485–490.
   PubMed Web of Science ®Google Scholar
• Busk M, Horsman MR, Jakobsen S, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008;70(4):1202–1212.
   PubMed Web of Science ®Google Scholar
• Skjøtskift T, Evensen ME, Furre T, et al. Dose painting for re-irradiation of head and neck cancer. Acta Oncol. 2018;57(12):1693–1699.
   PubMed Web of Science ®Google Scholar